Downregulating PRL-3 inhibit migration and invasion of lung cancer cell via RhoA and mDia1

Ming Jian¹,², Liu Nan³, Jiang Guocheng², Zhang Qingfu¹, Qiu Xueshan¹, and Wang Enhua¹

¹Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang; ²No.202 Hospital of People Liberation Army of China, Shenyang; ³Department of Pathology and Department of Nephrology, First Affiliated Hospital of China Medical University, Shenyang, PR China

ABSTRACT

Aims and background. The overexpression of phosphatase of regenerating liver-3 (PRL-3) affects the migration and invasion of epithelial cells. Little is known about the substrates or pathways that PRL-3 interacts with.

Methods. We studied the action and the mechanism of PRL-3 in migration and invasion of lung cancer. We detected the expression of PRL-3 in lung cancer cell lines and normal human bronchial epithelial cell.

Results. We found that PRL-3 expression was high in lung cancer cells. Knockdown of PRL-3 by siRNA inhibited cell migration and invasion and reorganized the cytoskeleton. Furthermore, blocking PRL-3 decreased RhoA activity and mDia1 expression. Blocking RhoA or mDia1 showed the similar changes of cytoskeleton and suppression of migration and invasion as inhibiting PRL-3 expression. Blocking RhoA inhibited the expression of mDia1.

Conclusions. These data indicate that downregulating PRL-3 inhibit cell migration and invasion by inactivating RhoA to downregulate mDia1 to reorganize cytoskeleton of lung cancer cells.

Key words: PRL-3, RhoA, mDia1, migration, invasion.

Acknowledgments: We thank Dr Cécile Rouleau and Dr Beverly Teicher from Genzyme Corp for the kind help in giving us the specific siRNA of PRL-3 and siRNA Negative-1 (Ambion).

Correspondence to: Qiu Xueshan, Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, No.92 North Second Road, Heping District, 110001, Shenyang, China. Tel 0086 24 2325 1638; email xueshan_qiu@hotmail.com

Received August 28, 2011; accepted December 29, 2011.